AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05153642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical intervention
Description: The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
Study NCT03762928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
Study NCT02557906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast reconstruction - implant and an ADM (SurgiMend)
Description: Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
Study NCT02557906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reconstruction- autologous tissue
Description: Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
Study NCT02557906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reconstruction- implant + dermal sling/LD flap
Description: Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
Study NCT01634958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid Phleum
Description: Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
Study NCT01394250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Cold, Vibrational Device
Study NCT01394250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Lidocaine 4% Cream
Description: Applied to anticipated IV site at least 30 minutes prior to cannulation.
Study NCT01614847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tears
Description: At random, subjects will receive isotonic artificial tear or a control (normal saline).
Study NCT01614847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: At random, subjects will receive isotonic artificial tear or a control (normal saline).
Study NCT04443439 — intervention group
Intervention type: DEVICE
Intervention: GE Discovery MR750 3.0t superconducting MRI
Description: T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
Study NCT02066350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single pancreas transplantation
Study NCT01962025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buttonhole needling technique
Description: the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
Study NCT04961736 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study NCT03729895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Oral Appliance
Description: Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
Study NCT01468922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Vascular endothelial growth factor (VEGFR) inhibitor
Study NCT01468922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor
Study NCT03762928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single administration of midazolam 2 mg oral solution
Study NCT03762928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: single administration of efavirenz 50 mg capsule
Study NCT00598611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: singel dose, oral, 20 mg
Study NCT00598611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: single dose, oral, 5 mg
Study NCT03839771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: 250mg tablets
Study NCT02054078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab200mg by intrapleural administration
Study NCT02054078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulvis talci
Description: Pulvis talci 4g by intrapleural administration
Study NCT03147066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Dezocine (0.1 mg/kg）will be infused during surgery
Study NCT03147066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
Study NCT01425164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: ivabradine tablets, 5 to 7.5 mg bis-in-die.
Study NCT01425164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: carvedilol tablets, 12.5 to 25 mg bis-in-die.
Study NCT01568827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackraspberry Slurry
Description: Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
Study NCT01887314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Ginger extract
Study NCT01887314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Ginger extract
Study NCT00649740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Sprinkle Capsules 25 mg
Description: 25mg, single dose fasting
Study NCT00649740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Sprinkle Capsule 25 mg
Description: 25mg, single dose fasting
Study NCT02264717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPECT
Description: Patients are randomized to either SPECT or Cardiac MRI
Study NCT02264717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: Patients are randomized to either SPECT or Cardiac MR
Study NCT01971034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV, Day 1, Day 8 and Day 15.
Study NCT01971034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg, PO, every 8 hours, daily.
Study NCT00895089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox)
Description: moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
Study NCT00895089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
Study NCT01192672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
Study NCT01192672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Writing
Description: Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
Study NCT03363542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruits, vegetables and/or whole grain high fiber rich diet
Description: Dietary education to Increase fruits, vegetables and/or high fiber intake
Study NCT01653093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging (3T MRI)
Description: Undergo 3T MRI
Study NCT01653093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI
Study NCT01653093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT01653093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: Undergo MR spectroscopy
Study NCT03709316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306 (Nirapairb)
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study NCT03709316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study NCT02934815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Description: The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
Study NCT01258296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25 mcg/hr transdermal patch
Study NCT01258296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive patch
Description: placebo patch (no drug)
Study NCT01589380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan.
Study NCT01589380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
Study NCT03298555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based intervention
Description: Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
Study NCT01567670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 2 mg x 1-2
Study NCT01567670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naloxone placebo
Description: h2o placebo spray
Study NCT04595526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced expiratory technique and induced sputum
Description: The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
Study NCT04595526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal suction
Description: Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
Study NCT02580214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact
Description: 600 ml of Impact, Nestle for 5 days prior to surgery
Study NCT01747629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study NCT03839771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AG-120
Description: 250mg tablets
Study NCT03839771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: 100mg tablets
Study NCT03839771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AG-221
Description: 100mg tablets
Study NCT02963558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cycle ergometry
Description: The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
Study NCT04246138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alignment types
Description: types of alignment mechanical versus kinematic of TKA to be studied
Study NCT01747629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study NCT02811042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraOnce
Description: Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
Study NCT02811042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Description: The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
Study NCT01063127 — intervention group
Intervention type: OTHER
Intervention: Study on insulin sensitivity after diet or bariatric surgery
Description: Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
Study NCT01063127 — intervention group
Intervention type: OTHER
Intervention: gastric bypass
Description: Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
Study NCT02526771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional lymph node dissection
Description: conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
Study NCT02526771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unconventional lymph node dissection
Description: unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
Study NCT03081351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended lymphadenectomy and nerve clearance
Description: The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node.
Study NCT03081351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard lymphadenectomy
Description: The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
Study NCT02605772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
Study NCT02605772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
Study NCT02605772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
Study NCT02371161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DHAP/R-ICE
Description: R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Solution 1
Description: 50g glucose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Solution 2
Description: 50g glucose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Solution 3
Description: 50g glucose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 100:0
Description: 50g sucrose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 0:100
Description: 50g isomaltulose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 50:50
Description: 25g sucrose and 25g isomaltulose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 60:40
Description: 30g sucrose and 20g isomaltulose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 70:30
Description: 35g sucrose and 15g isomaltulose dissolve in 300ml of water
Study NCT04653207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 80:20
Description: 40g sucrose and 10g isomaltulose dissolve in 300ml of water
Study NCT01081730 — intervention group
Intervention type: BIOLOGICAL
Intervention: anti-TNF biologics
Description: as prescribed
Study NCT01081730 — intervention group
Intervention type: OTHER
Intervention: general population
Description: non-treated cohort
Study NCT01081730 — intervention group
Intervention type: BIOLOGICAL
Intervention: non-anti-TNF biologics
Description: as prescribed
Study NCT01081730 — intervention group
Intervention type: BIOLOGICAL
Intervention: ustekinumab
Description: as prescribed
Study NCT01081730 — intervention group
Intervention type: DRUG
Intervention: systemic non-biological treatments
Description: as prescribed
Study NCT01261455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Location of the autograft taken following pterygium excision
Description: Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
Study NCT01261455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Location of the autograft taken following pterygium excision
Description: Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
Study NCT02958475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support Group (Facebook)
Description: The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.